Wird geladen...

How recent advances in immunotherapy are changing the standard of care for patients with metastatic melanoma

In 2011, two therapies were approved for the treatment of metastatic melanoma: ipilimumab, an immunotherapeutic agent, and vemurafenib, a BRAF kinase inhibitor. These approvals were based on data from phase III trials, which showed that treatment with these agents produced substantial improvements i...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Ann Oncol
1. Verfasser: Wolchok, J.
Format: Artigo
Sprache:Inglês
Veröffentlicht: Oxford University Press 2012
Schlagworte:
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6278954/
https://ncbi.nlm.nih.gov/pubmed/22918923
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mds258
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!